Compounds that inhibit mcl-1 protein
US-2017088560-A1 · Mar 30, 2017 · US
Compounds that inhibit MCL-1 protein
US10836779B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10836779-B2 |
| Application number | US-201816121750-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 5, 2018 |
| Priority date | Aug 29, 2014 |
| Publication date | Nov 17, 2020 |
| Grant date | Nov 17, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer, the method comprising: administering to a patient in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the cancer is a hematologic malignancy selected from multiple myeloma, non-Hodgkin's lymphoma, or acute myelogenous leukemia, wherein the compound has a structure selected from: 2. The method of claim 1 , wherein the cancer is acute myelogenous leukemia. 3. The method of claim 1 , wherein the cancer is multiple myeloma. 4. The method of claim 1 , wherein the cancer is non-Hodgkin's lymphoma. 5. The method of claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof is: 6. The method of claim 5 , wherein the cancer is acute myelogenous leukemia. 7. The method of claim 5 , wherein the cancer is multiple myeloma. 8. The method of claim 5 , wherein the cancer is non-Hodgkin's lymphoma.
Assignees
Inventors
Classifications
against tumor tissues, cells, antigens · CPC title
having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title
- C07D513/10Primary
Spiro-condensed systems · CPC title
- C07D513/08Primary
Bridged systems · CPC title
the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10836779B2 cover?
- Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided…
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).